“This clinical data on 4D-150 marks an important milestone for 4DMT,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. 4D Molecular Therapeutics will host a conference call today, Monday Novemat 8:00 AM E.T. The data focused on safety, tolerability, aflibercept transgene expression and anti-VEGF clinical activity of the 4D-150 genetic medicine in patients enrolled in cohort 1 (n=5 3E10 vg/eye) the data cutoff date was October 13, 2022. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced interim clinical data from cohort 1 of the Phase 1/2 clinical trial of intravitreal 4D-150 for wet AMD.

14, 2022 (GLOBE NEWSWIRE) - 4D Molecular Therapeutics, Inc. Conference call & webcast to be held Monday Novemat 8:00 AM E.T.ĮMERYVILLE, Calif., Nov.Cohort 1 safety and tolerability of 4D-150 demonstrated to date, with no clinically significant intraocular inflammation or hypotony reported.80% of Cohort 1 patients had not received any supplemental aflibercept injections for up to ~10 months after 4D-150 dosing.Following intravitreal 4D-150, Cohort 1 patients’ annualized anti-VEGF injection rate was reduced by 96.7%.Cohort 1 patients (n=5) received a single intravitreal injection of 4D-150 (3E10 vg/eye) these patients were high need patients who in the 12 months preceding trial enrollment had a mean annualized anti-VEGF injection rate of ~11.

Max yang 4d molecular therapeutics